Literature DB >> 18954738

Molecular biology and genetics of lymphomas.

Elena M Hartmann1, German Ott, Andreas Rosenwald.   

Abstract

This article summarizes molecular and genetic features of B-cell non-Hodgkin lymphoma and focuses on diffuse large B-cell lymphoma, Burkitt lymphoma, follicular lymphoma, and mantle cell lymphoma. In each of these entities, hallmark genetic aberrations, cytogenetic characteristics, and alterations of single genes that might be involved in the pathogenesis and molecular evolution of the tumor are described. Recent results from gene-expression profiling studies are incorporated that are relevant for the classification of lymphoma entities, the prediction of their clinical behavior, and the identification of deregulated signal-transduction pathways that might represent potential targets in future therapeutic approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18954738     DOI: 10.1016/j.hoc.2008.07.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  14 in total

1.  Epstein-Barr virus-specific CD8(+) T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired.

Authors:  D Cárdenas; G Vélez; A Orfao; M V Herrera; J Solano; M Olaya; A M Uribe; C Saavedra; M Duarte; M Rodríguez; M López; S Fiorentino; S Quijano
Journal:  Clin Exp Immunol       Date:  2015-09-11       Impact factor: 4.330

2.  Refining tumor-associated aneuploidy through 'genomic recoding' of recurrent DNA copy number aberrations in 150 canine non-Hodgkin lymphomas.

Authors:  Rachael Thomas; Eric L Seiser; Alison Motsinger-Reif; Luke Borst; Victor E Valli; Kathryn Kelley; Steven E Suter; David Argyle; Kristine Burgess; Jerold Bell; Kerstin Lindblad-Toh; Jaime F Modiano; Matthew Breen
Journal:  Leuk Lymphoma       Date:  2011-03-07

Review 3.  Novel therapeutics for aggressive non-Hodgkin's lymphoma.

Authors:  Daruka Mahadevan; Richard I Fisher
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  Secondary abnormalities involving 1q or 13q and poor outcome in high stage Burkitt leukemia/lymphoma cases with 8q24 rearrangement at diagnosis.

Authors:  Mariana Tavares de Souza; Hasmik Mkrtchyan; Rocio Hassan; Daniela Ribeiro Ney-Garcia; Alice Maria Boulhosa de Azevedo; Elaine Sobral da Costa; Amanda Faria de Figueiredo; Thomas Liehr; Eliana Abdelhay; Maria Luiza Macedo Silva
Journal:  Int J Hematol       Date:  2011-01-05       Impact factor: 2.490

5.  Curcumin nanodisk-induced apoptosis in mantle cell lymphoma.

Authors:  Amareshwar T K Singh; Mistuni Ghosh; Trudy M Forte; Robert O Ryan; Leo I Gordon
Journal:  Leuk Lymphoma       Date:  2011-06-24

6.  Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma.

Authors:  Rebecca A Barnard; Luke A Wittenburg; Ravi K Amaravadi; Daniel L Gustafson; Andrew Thorburn; Douglas H Thamm
Journal:  Autophagy       Date:  2014-05-20       Impact factor: 16.016

Review 7.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

Review 8.  Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.

Authors:  David T Teachey; Stephan A Grupp; Valerie I Brown
Journal:  Br J Haematol       Date:  2009-03-16       Impact factor: 6.998

9.  The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.

Authors:  E Ferretti; C Tripodo; G Pagnan; C Guarnotta; D Marimpietri; M V Corrias; D Ribatti; S Zupo; G Fraternali-Orcioni; J L Ravetti; V Pistoia; A Corcione
Journal:  Leukemia       Date:  2014-10-06       Impact factor: 11.528

10.  NF-κB p65 represses microRNA-124 transcription in diffuse large B-cell lymphoma.

Authors:  Hyein Shim; Jehyun Nam; Sang-Woo Kim
Journal:  Genes Genomics       Date:  2020-03-23       Impact factor: 1.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.